What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
Mark S. Freedman mainly investigates Multiple sclerosis, Internal medicine, Surgery, Placebo and Expanded Disability Status Scale.
His Multiple sclerosis research includes elements of Hematopoietic stem cell transplantation, Transplantation, MEDLINE, Pathology and Intensive care medicine.
His Internal medicine research integrates issues from Gastroenterology and Teriflunomide.
His Surgery research incorporates elements of Nerve fiber layer, Ophthalmology, Optic nerve and Clinically isolated syndrome.
His work carried out in the field of Placebo brings together such families of science as Siponimod and Adverse effect, Tolerability, Clinical trial, Intention-to-treat analysis.
His Expanded Disability Status Scale study combines topics in areas such as Placebo-controlled study and Interferon beta-1b.
His most cited work include:
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (1618 citations)
- Defining the clinical course of multiple sclerosis: The 2013 revisions (1374 citations)
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis (628 citations)
What are the main themes of his work throughout his whole career to date?
Mark S. Freedman mainly focuses on Multiple sclerosis, Internal medicine, In patient, Placebo and Surgery.
His Multiple sclerosis study is concerned with the field of Immunology as a whole.
He interconnects Gastroenterology, Teriflunomide, Expanded Disability Status Scale and Oncology in the investigation of issues within Internal medicine.
His Expanded Disability Status Scale research is multidisciplinary, incorporating elements of Physical therapy and Hazard ratio.
His work investigates the relationship between Placebo and topics such as Clinically isolated syndrome that intersect with problems in Interferon beta-1b and McDonald criteria.
Many of his studies on Surgery involve topics that are commonly interrelated, such as Interferon beta-1a.
He most often published in these fields:
- Multiple sclerosis (79.95%)
- Internal medicine (49.74%)
- In patient (24.22%)
What were the highlights of his more recent work (between 2017-2021)?
- Multiple sclerosis (79.95%)
- Internal medicine (49.74%)
- In patient (24.22%)
In recent papers he was focusing on the following fields of study:
His main research concerns Multiple sclerosis, Internal medicine, In patient, Teriflunomide and Placebo.
His Multiple sclerosis study integrates concerns from other disciplines, such as Hematopoietic stem cell transplantation, Disease, Clinical trial, Disability progression and Neurology.
The concepts of his Hematopoietic stem cell transplantation study are interwoven with issues in Treatment response, Quality of life, Immune system and Intensive care medicine.
His work deals with themes such as Gastroenterology, Expanded Disability Status Scale and Oncology, which intersect with Internal medicine.
Mark S. Freedman combines subjects such as Extension study, Protective immunity, Lymphocyte, Physical therapy and Pooled analysis with his study of Teriflunomide.
His Placebo research includes elements of Post-hoc analysis, Phases of clinical research and Clinically isolated syndrome.
Between 2017 and 2021, his most popular works were:
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (50 citations)
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial (44 citations)
- Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. (32 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His primary areas of investigation include Multiple sclerosis, Internal medicine, Clinical trial, Placebo and Hematopoietic stem cell transplantation.
He has researched Multiple sclerosis in several fields, including Adverse effect, Disease, Neurology, Pediatrics and Transplantation.
The concepts of his Internal medicine study are interwoven with issues in Teriflunomide, Expanded Disability Status Scale, Oncology and Gastroenterology.
His work carried out in the field of Clinical trial brings together such families of science as Pathological, Spinal cord involvement, Myelopathy, Spinal cord and Neuromyelitis Optica Spectrum Disorders.
His Placebo research incorporates elements of Clinical endpoint and Phases of clinical research.
His Hematopoietic stem cell transplantation study combines topics in areas such as CD58, Immune system and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
